210 related articles for article (PubMed ID: 10383540)
21. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
[TBL] [Abstract][Full Text] [Related]
22. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
[TBL] [Abstract][Full Text] [Related]
23. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
24. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
[TBL] [Abstract][Full Text] [Related]
25. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
Wienkers LC; Steenwyk RC; Mizsak SA; Pearson PG
Drug Metab Dispos; 1995 Mar; 23(3):383-92. PubMed ID: 7628305
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.
Leemann T; Transon C; Dayer P
Life Sci; 1993; 52(1):29-34. PubMed ID: 8417277
[TBL] [Abstract][Full Text] [Related]
27. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
Galetin A; Houston JB
J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
[TBL] [Abstract][Full Text] [Related]
29. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
30. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
32. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.
Kanamitsu S; Ito K; Sugiyama Y
Pharm Res; 2000 Mar; 17(3):336-43. PubMed ID: 10801223
[TBL] [Abstract][Full Text] [Related]
33. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.
Bonnabry P; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 49(4):305-8. PubMed ID: 8857077
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
Miners JO; Birkett DJ
Br J Clin Pharmacol; 1998 Jun; 45(6):525-38. PubMed ID: 9663807
[TBL] [Abstract][Full Text] [Related]
35. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
36. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
Bajpai M; Roskos LK; Shen DD; Levy RH
Drug Metab Dispos; 1996 Dec; 24(12):1401-3. PubMed ID: 8971149
[No Abstract] [Full Text] [Related]
37. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
Andersson TB; Bredberg E; Ericsson H; Sjöberg H
Drug Metab Dispos; 2004 Jul; 32(7):715-21. PubMed ID: 15205386
[TBL] [Abstract][Full Text] [Related]
38. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica.
Ishihara K; Kushida H; Yuzurihara M; Wakui Y; Yanagisawa T; Kamei H; Ohmori S; Kitada M
J Pharm Pharmacol; 2000 Aug; 52(8):1023-9. PubMed ID: 11007075
[TBL] [Abstract][Full Text] [Related]
39.
Morita K; Kato M; Kudo T; Ito K
Xenobiotica; 2020 Sep; 50(9):1064-1075. PubMed ID: 32125203
[No Abstract] [Full Text] [Related]
40. An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates.
Jones BC; Srivastava A; Colclough N; Wilson J; Reddy VP; Amberntsson S; Li D
Drug Metab Dispos; 2017 Oct; 45(10):1060-1067. PubMed ID: 28784689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
